Comparing barriers to early stage diagnosis of hepatocellular carcinoma between safety net hospitals and academic medical centers: An analysis from the United States Safety-Net Collaborative.
HCC
racial bias
screening
social determinants of health
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
revised:
15
05
2024
received:
07
11
2023
accepted:
20
07
2024
medline:
1
8
2024
pubmed:
1
8
2024
entrez:
1
8
2024
Statut:
aheadofprint
Résumé
Early detection of hepatocellular carcinoma (HCC) is associated with improved survival. However, a greater proportion of patients treated at safety net hospitals (SNHs) present with late-stage disease compared to those at academic medical centers (AMCs). This study aims to identify barriers to diagnosis of HCC, highlighting differences between SNHs and AMCs. The US Safety Net Collaborative-HCC database was queried. Patients were stratified by facility of diagnosis (SNH or AMC). Patient demographics and HCC screening rates were examined. The primary outcome was stage at diagnosis (AJCC I/II-"early"; AJCC III/IV-"late"). 1290 patients were included; 50.2% diagnosed at SNHs and 49.8% at AMCs. At SNHs, 44.4% of patients were diagnosed late, compared to 27.6% at AMCs. On multivariable regression, Black race was associated with late diagnosis in both facilities (SNH: odds ratio 1.96, p = 0.03; AMC: 2.27, <0.01). Screening was associated with decreased odds of late diagnosis (SNH: 0.46, p = 0.04; AMC: 0.37, p < 0.01). Black race was associated with late diagnosis of HCC, while screening was associated with early diagnosis across institutional types. These results suggest socially constructed racial bias in screening and diagnosis of HCC. Screening efforts targeting SNH patients and Black patients at all facilities are essential to reduce disparities.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Early detection of hepatocellular carcinoma (HCC) is associated with improved survival. However, a greater proportion of patients treated at safety net hospitals (SNHs) present with late-stage disease compared to those at academic medical centers (AMCs). This study aims to identify barriers to diagnosis of HCC, highlighting differences between SNHs and AMCs.
METHODS
METHODS
The US Safety Net Collaborative-HCC database was queried. Patients were stratified by facility of diagnosis (SNH or AMC). Patient demographics and HCC screening rates were examined. The primary outcome was stage at diagnosis (AJCC I/II-"early"; AJCC III/IV-"late").
RESULTS
RESULTS
1290 patients were included; 50.2% diagnosed at SNHs and 49.8% at AMCs. At SNHs, 44.4% of patients were diagnosed late, compared to 27.6% at AMCs. On multivariable regression, Black race was associated with late diagnosis in both facilities (SNH: odds ratio 1.96, p = 0.03; AMC: 2.27, <0.01). Screening was associated with decreased odds of late diagnosis (SNH: 0.46, p = 0.04; AMC: 0.37, p < 0.01).
CONCLUSIONS
CONCLUSIONS
Black race was associated with late diagnosis of HCC, while screening was associated with early diagnosis across institutional types. These results suggest socially constructed racial bias in screening and diagnosis of HCC. Screening efforts targeting SNH patients and Black patients at all facilities are essential to reduce disparities.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209‐249.
Schwartz J, Carithers R, Tanabe K, Di Bisceglie A. Epidemiology and Risk Factors for Hepatocellular Carcinoma. UpToDate; 2022.
Healthcare Consumer Navigator Center. Safety Net Hospitals; A Resource for the Healthcare Consumers; 2024. https://healthcareconsumernavigatorcenter.com/consumer-information-navigator/section-4/safety-net-hospitals-resource-healthcare-consumers/
Vitiello GA, Wang A, Lee RM, et al. Surgical resection of early stage hepatocellular carcinoma improves patient survival at safety net hospitals. J Surg Oncol. 2021;123(4):963‐969.
Kronenfeld JP, Ryon EL, Goldberg D, et al. Disparities in presentation at time of hepatocellular carcinoma diagnosis: a United States Safety‐Net Collaborative study. Ann Surg Oncol. 2021;28(4):1929‐1936.
Poulson MR, Blanco BA, Geary AD, et al. The role of racial segregation in treatment and outcomes among patients with hepatocellular carcinoma. HPB. 2021;23(6):854‐860.
Mitchell B, Franco J. HOLC “Redlining” Maps: The Persistent Structure Of Segregation And Economic Inequality. 2018. Accessed December 19, 2022. Available from: https://ncrc.org/holc/
Turgeon MK, Lee RM, Gamboa AC, et al. Impact of hepatitis C treatment on long‐term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative study. HPB. 2021;23(3):422‐433.
Melia MT, Muir AJ, McCone J, et al. Racial differences in hepatitis C treatment eligibility. Hepatology. 2011;54(1):70‐78.
Sims OT, Pollio DE, Hong BA, North CS. Racial disparities in hepatitis C treatment eligibility. Ann Hepatol. 2017;16(4):530‐537.
Castaldi M, Smiley A, Kechejian K, Butler J, Latifi R. Disparate access to breast cancer screening and treatment. BMC Womens Health. 2022;22(1):249.
Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El‐Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52(1):132‐141.
Lee RM, Darby R, Medin CR, et al. Implementation of a hepatocellular carcinoma screening program for at‐risk patients Safety‐Net Hospital: a model for national dissemination. Ann Surg. 2022;276(3):545‐553.
Chou R, Dana T, Fu R, et al. Screening for hepatitis C virus infection in adolescents and adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2020;323:976.
Khan GK, Harvey L, Johnson S, et al. Integration of a community‐based harm reduction program into a safety net hospital: a qualitative study. Harm Reduct J. 2022;19(1):35.
Rogal SS, McCarthy R, Reid A, et al. Primary care and hepatology provider‐perceived barriers to and facilitators of hepatitis C treatment candidacy and adherence. Dig Dis Sci. 2017;62(8):1933‐1943.
Eckhardt B, Mateu‐Gelabert P, Aponte‐Melendez Y, et al. Accessible hepatitis C care for people who inject drugs: A randomized clinical trial. JAMA Intern Med. 2022;182(5):494‐502.
Simmons OL, Feng Y, Parikh ND, Singal AG. Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance. Clin Gastroenterol Hepatol. 2019;17(4):766‐773.
Singal AG, Tiro JA, Murphy CC, et al. Mailed outreach invitations significantly improve HCC surveillance rates in patients with cirrhosis: a randomized clinical trial. Hepatology. 2019;69(1):121‐130.
Kanwal F, Khaderi S, Singal AG, et al. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023;75(3):997‐1005.
Muthukrishnan M, Arnold LD, James AS. Patients’ self‐reported barriers to colon cancer screening in federally qualified health center settings. Prev Med Rep. 2019;15:100896.